Segall Bryant & Hamill LLC Boosts Stock Holdings in Embecta Corp. (NASDAQ:EMBC)

Segall Bryant & Hamill LLC increased its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 40.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,145 shares of the company's stock after purchasing an additional 42,836 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.25% of Embecta worth $3,059,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its holdings in shares of Embecta by 175.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company's stock worth $25,000 after purchasing an additional 774 shares in the last quarter. Quarry LP purchased a new stake in Embecta in the third quarter worth approximately $30,000. Oppenheimer Asset Management Inc. bought a new stake in Embecta in the 4th quarter worth approximately $209,000. KLP Kapitalforvaltning AS purchased a new stake in Embecta during the 4th quarter valued at $215,000. Finally, Intech Investment Management LLC bought a new position in shares of Embecta during the 3rd quarter valued at $211,000. 93.83% of the stock is owned by hedge funds and other institutional investors.

Embecta Price Performance

Shares of EMBC traded down $0.12 on Tuesday, reaching $12.63. The company's stock had a trading volume of 436,747 shares, compared to its average volume of 441,196. The stock's 50 day simple moving average is $15.02 and its two-hundred day simple moving average is $16.23. The stock has a market capitalization of $734.23 million, a P/E ratio of 12.63, a PEG ratio of 0.78 and a beta of 1.27. Embecta Corp. has a 12-month low of $9.93 and a 12-month high of $21.48.

Remove Ads

Embecta (NASDAQ:EMBC - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Analysts expect that Embecta Corp. will post 2.85 earnings per share for the current year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 4.75%. The ex-dividend date was Friday, February 28th. Embecta's payout ratio is 60.00%.

Insider Transactions at Embecta

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the completion of the sale, the director now owns 36,133 shares in the company, valued at approximately $591,858.54. This represents a 7.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.42% of the company's stock.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Embecta from an "underweight" rating to an "equal weight" rating and lifted their price objective for the stock from $13.00 to $20.00 in a report on Monday, December 2nd.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.